

27 Nov 2022 | News

# Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer's meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck's Frazier cautions against profit maximization.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 25 November 2022, including: a preview of the CTAD Alzheimer's meeting; US myeloma drug withdrawal puts pressure on [\*GSK plc\*](#); [\*uniQure N.V./CSL Limited\*](#)'s gene therapy sets record US price; new leadership at [\*Teva Pharmaceutical Industries Ltd.\*](#); and [\*Merck & Co., Inc.\*](#)'s Frazier cautions against profit maximization.

This and all our other podcasts are available on the Pharma Intelligence channel on [\*Apple Podcasts\*](#), [\*Google Podcasts\*](#), [\*SoundCloud\*](#), [\*TuneIn\*](#) and [\*Spotify Podcasts\*](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[\*CTAD 2022 Preview: Lecanemab Is Headliner After Gantenerumab's Failure\*](#)" - Scrip, 22 Nov, 2022.)

(Also see "[\*Blenrep US Withdrawal Is A Big Blow To GSK's Blockbuster Hopes\*](#)" - Scrip, 22 Nov, 2022.)

(Also see "[\*UniQure/CSL Set To Launch First Hemophilia B Gene Therapy Next Year At Record Price\*](#)" - Scrip, 23 Nov, 2022.)

(Also see "[\*Teva's New CEO Francis Takes Over A Steadier – Though Still Rocky – Organization\*](#)" - Scrip, 21 Nov, 2022.)

(Also see "[\*Departing Words: Merck's Ken Frazier Cautions Against Profit Maximization\*](#)" - Scrip, 21 Nov, 2022.)

[Click here to explore this interactive content online](#) ✎